PT  - JOURNAL ARTICLE
AU  - Lui, Vincent Chi-Hang
AU  - Hui, Kenrie Pui-Yan
AU  - Babu, Rosanna Ottakandathil
AU  - Yue, Haibing
AU  - Chung, Patrick Ho-Yu
AU  - Tam, Paul Kwong-Hang
AU  - Chan, Michael Chi-Wai
AU  - Wong, Kenneth Kak-Yuen
TI  - Human liver organoid derived intra-hepatic bile duct cells support SARS-CoV-2 infection and replication and its comparison with SARS-CoV
AID  - 10.1101/2021.02.10.21251458
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.10.21251458
4099  - http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251458.short
4100  - http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251458.full
AB  - Background Although the main route of infection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the respiratory tract, liver injury is also commonly seen in many patients, as evidenced by deranged parenchymal liver enzymes. Furthermore, patients with severe liver disease have been shown to have higher mortality. Overall, the mechanism behind the liver injury remains unclear.Approach and results We showed that intra-hepatic bile duct cells could be grown using a human liver organoid platform. The cholangiocytes were not only susceptible to SARS-CoV-2 infection, they also supported efficient viral replication. We also showed that SARS-CoV-2 replication was much higher than SARS-CoV.Conclusion Our findings suggested direct cytopathic viral damage being a mechanism for SARS-CoV-2 liver injury.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no external funding for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hong Kong West Cluster-Hong Kong University Cluster Research Ethics Committee/Institutional Review Board (UW 16-052)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request to corresponding authors